In 2023, antiarrhythmic medicine use varied across different countries, with Belgium and Italy leading at 7.7 units per thousand persons daily. Compared to previous years, usage in these countries saw marginal declines, with Belgium decreasing by 0.76% and Italy by 0.26%. Notably, South Korea experienced a significant increase of 11.38%, whereas Portugal and Luxembourg saw notable declines of 3.89% and 3.52%, respectively. Across a range of countries, larger variances are evident with countries like Norway and Chile showing increases, while Israel, Austria, and Finland displayed a downtrend.
Future trends to watch for include potential further growth in South Korea, likely driven by healthcare advancements and increased awareness. Stability in countries like New Zealand and Australia could suggest mature markets with established consumption patterns. Continuing decline in countries like Portugal may reflect changing healthcare policies or competitive treatment options. Monitoring these deviations will be crucial for understanding global demand patterns for antiarrhythmic medicines.
Top countries in Antiarrhythmic Medicine Use by Country
| # | 10 Countries | Units (Defined Daily Dosage) Per Thousand Persons Per Day | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Belgium | 7.7 | 2023 | 0% | -0.76% | View data |
| 2 | 2 Italy | 7.7 | 2023 | 0% | -0.26% | View data |
| 3 | 3 Hungary | 6.4 | 2023 | +1.59% | -0.61% | View data |
| 4 | 4 Luxembourg | 5.6 | 2023 | -1.75% | -3.52% | View data |
| 5 | 5 Portugal | 4.1 | 2023 | -4.65% | -3.89% | View data |
| 6 | 6 Israel | 3.4 | 2023 | -2.86% | -2.2% | View data |
| 7 | 7 Germany | 2.9 | 2023 | 0% | -0.68% | View data |
| 8 | 8 Norway | 2.8 | 2023 | +3.7% | +3.13% | View data |
| 9 | 9 South Korea | 2.4 | 2023 | +9.09% | +11.38% | View data |
| 10 | 10 Australia | 2.3 | 2023 | 0% | +1.84% | View data |
